PHARMACEUTICALS

Our portfolio of sublingual pharmaceutical products is built on the WaferiX platform technology, and includes pipeline products in the late stage of development

No.
Active
Indication
Clinical Studies
Pharmaceuticals
Pre Clinical
P1
P2
P3
Marketing Approval
1
Wafesil
Male erectile dysfunction
2
Wafermine
CRPS, Depression
3
iXB 401
Obesity, Diabetes
4
NAD+
Sarcopenia
5
iXB 120
Acute agitation
6
iXB 321
Influenza vaccine
7
iXB 322
Respiratory Viral Prophylaxis

Wafermine

World’s first sublingual ketamine for acute moderate to severe pain.

Phase 3-ready for acute pain, Phase 2-ready for Complex Regional Pain Syndrome and Depression

Non-opioid with opioid sparing effects
Positive in Phase 2b clinical studies:

  • Strong analgesic effect
  • Safe and tolerable
LEARN MORE

iXB 401

Sublingual semaglutide wafers for the treatment of diabetes and obesity

Formulated with WaferlogiX to address poor oral bioavailability of Semaglutide (~1%), by adding sublingual absorption to improve bioavailability and lower variability of absorption.

Preclinical studies in mice and rats show significantly improved absorption of Semaglutide compared to Rybelsus

Dexmedetomidine

Sublingual dexmedetomidine wafer for the treatment of acute agitation in dementia.

Completed Phase 1 Sublingual Dexmedetomidine Clinical Study

The Phase 1 pharmacokinetic clinical study achieved several positive results:
1. High bioavailability: The sublingual wafer showed an impressive 70-80% absolute bioavailability across all dosages tested.
2. Fast onset of action: The sublingual wafer achieved a peak drug concentration in 1.5 hours (Tmax), with drug detectable in plasma as early as 5 minutes post dosing.
3. Dose proportional: The drug exposure was proportional across the dosing range.
4. Safety profile: Sublingual wafers were safe and well tolerated; there were no serious adverse events.

LEARN MORE

Bnox

Improved bioavailability from other sublingual buprenorphine products.

By utilising iX Biopharma’s proprietary sublingual technology WaferiX, we have demonstrated in a phase 1 pharmacokinetic study (BUP001) that BnoX facilitates the rapid absorption of buprenorphine (median Tmax 1.0 hour) with greater absolute bioavailability of 45%. These results suggest superior pharmacokinetics to currently marketed sublingual buprenorphine formulations.

LEARN MORE

Wafesil & Silcap

Sildenafil for the treatment of erectile dysfunction in unique dosage forms.

Sildenafil citrate has been shown to be a hallmark drug for the treatment of erectile dysfunction in males. Utilising WaferiX, Wafesil is a sildenafil wafer that is administered sublingually. Wafesil comes in a new dosage form and route of administration for patients who cannot or prefer not to swallow. Wafesil is approved for marketing in Australia, outlicensed for China market.

Silcap is a novel small sildenafil capsule that is easy to swallow. Silcap is approved for marketing in Australia and Singapore.

Scientific Publications